Pulmonary Arterial Hypertension Clinical Trials

26 studies are recruiting for pulmonary arterial hypertension in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

   Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still b…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Heart, Lung, and Blood Institute (NHLBI)

   See if you can join NCT07613099 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

   The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   USA012, Los Angeles, California

   Locations

   26 in total

   Run by

   Insmed Incorporated

   See if you can join NCT07481981 on ClinicalTrials.gov

3. A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults

   Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Investigational Site-102, Tampa, Florida

   Locations

   4 in total

   Run by

   35Pharma Inc

   See if you can join NCT07143448 on ClinicalTrials.gov

4. Spironolactone for Pulmonary Arterial Hypertension

   Background: - High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high. Lung blood vessel function can be harmed by progressive injuries, such as inflammation, leading to …

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institutes of Health Clinical Center (CC)

   See if you can join NCT01712620 on ClinicalTrials.gov

5. A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

   Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) tre…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Arizona Pulmonary Specialists ( Site 1010), Scottsdale, Arizona

   Locations

   136 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07218029 on ClinicalTrials.gov

6. An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

   This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   Arizona Pulmonary Specialists, LTD, Scottsdale, Arizona

   Locations

   43 in total

   Run by

   Inhibikase Therapeutics

   See if you can join NCT07365332 on ClinicalTrials.gov

7. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

   The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

   Stage

   Not phased

   Ages

   0 to 20

   Site

   Lucile Packard Children's Hospital, Palo Alto, California

   Locations

   52 in total

   Run by

   Duke University

   See if you can join NCT04278404 on ClinicalTrials.gov

8. The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

   Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years. Increasing physical activity is highly efficacious in PAH, resulting in six-minute walk di…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Run by

   Vanderbilt University Medical Center

   See if you can join NCT05464095 on ClinicalTrials.gov

9. Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

   Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The Johns Hopkins Hospital, Baltimore, Maryland

   Locations

   3 in total

   Run by

   Gustavo A Heresi, MD, MS

   See if you can join NCT06992440 on ClinicalTrials.gov

10. Xenon MRI Pulm Hypertension

    The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or t…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Duke University Medical Center, Durham, North Carolina

    Run by

    Bastiaan Driehuys

    See if you can join NCT04991454 on ClinicalTrials.gov

11. A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)

    This pilot clinical trial will evaluate the initial safety, feasibility, and pharmacokinetics of microbiota transplant therapy (MTT) with antibiotic pre-conditioning and fiber supplementation vs. placebo in patients with pulmonary arterial hypertension (PAH). This trial will inform development of f…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    University of Minnesota, Minneapolis, Minnesota

    Run by

    University of Minnesota

    See if you can join NCT06481852 on ClinicalTrials.gov

12. Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

    This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

    Stage

    Phase 3

    Ages

    18 to 75

    Site

    Valley Advanced Lung Diseases Institute, Fresno, California

    Locations

    120 in total

    Run by

    Gossamer Bio USA, Inc.

    See if you can join NCT06274801 on ClinicalTrials.gov

13. A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia

    In this study, the investigators will follow two small cohorts of pregnant women: a cohort of healthy women with uncomplicated pregnancies residing at high altitude, a control group of healthy women with uncomplicated pregnancies residing at sea level, to characterize differences in cardiopulmonary…

    Stage

    Not phased

    Ages

    18 to 45

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT07312227 on ClinicalTrials.gov

14. Repurposing Valsartan May Protect Against Pulmonary Hypertension

    This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    University of Washington Medical Center, Seattle, Washington

    Run by

    University of Washington

    See if you can join NCT06053580 on ClinicalTrials.gov

15. Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

    The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.

    Stage

    Phase 2

    Ages

    1 to 17

    Site

    The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606), Los Angeles, California

    Locations

    35 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT05587712 on ClinicalTrials.gov

16. Mobile Health Intervention to Improve Exercise in Pediatric PH

    Children and adults with pulmonary arterial hypertension (PAH) have severely reduced daily activity compared to healthy populations. In adults, investigators recently demonstrated that lower baseline daily step counts associated with increased risk of hospitalization and worsening WHO functional cl…

    Stage

    Not phased

    Ages

    10 to 21

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT06549452 on ClinicalTrials.gov

17. Pulmonary Hypertension SOLAR

    The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signat…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Duke University Medical Center, Durham, North Carolina

    Run by

    Bastiaan Driehuys

    See if you can join NCT04778046 on ClinicalTrials.gov

18. 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

    The overall study objectives outlined in this study are to derive 129Xe MRI pulmonary vascular biomarker signatures that differentiate common subtypes of PAH and to determine the ability of 129Xe MRI to longitudinally monitor disease progression and response to therapy in PAH, with the aid of addit…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Duke University Medical Center, Durham, North Carolina

    Run by

    Bastiaan Driehuys

    See if you can join NCT06104228 on ClinicalTrials.gov

19. 129 Xenon Imaging in Patients Treated With Sotatercept

    Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Duke University Medical Center, Durham, North Carolina

    Run by

    Bastiaan Driehuys

    See if you can join NCT06351345 on ClinicalTrials.gov

20. PET Image in PAH Patients

    Pulmonary arterial hypertension (PAH) is mortal disease affecting the blood vessels of the lung. Despite its morbid prognosis, PAH is often misdiagnosed or ignored, with an average time of 44 months between onset of symptoms to diagnosis and substantial progression of disease severity. Therefore, a…

    Stage

    EARLY_Phase 1

    Ages

    18 to 75

    Site

    Montefiore Hospital Clinical and Translational Research Center, Pittsburgh, Pennsylvania

    Run by

    Stephen Y. Chan

    See if you can join NCT05452889 on ClinicalTrials.gov

21. Pulmonary Hypertension Association Registry

    The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care C…

    Stage

    Not phased

    Ages

    0 and older

    Site

    Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona

    Locations

    52 in total

    Run by

    Pulmonary Hypertension Association, Inc.

    See if you can join NCT04071327 on ClinicalTrials.gov

22. Rutgers University Study of the Genetics of Pulmonary Hypertension

    The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligible, and a diagnosis of PH is NOT required. Study participation is online, and it takes about 20 minutes to complete health surveys and reques…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Rutgers University, Piscataway, New Jersey 08854, Piscataway, New Jersey

    Run by

    Rutgers, The State University of New Jersey

    See if you can join NCT07217522 on ClinicalTrials.gov

23. Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

    This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California-Los Angeles, Los Angeles, California

    Locations

    12 in total

    Run by

    Aria CV, Inc

    See if you can join NCT04555161 on ClinicalTrials.gov

24. Pulmonary Hypertension Biorepository and Registry

    Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Kansas Medical Center, Kansas City, Kansas

    Run by

    University of Kansas Medical Center

    See if you can join NCT04808596 on ClinicalTrials.gov

25. Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

    Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe t…

    Stage

    Not phased

    Ages

    0 to 21

    Site

    Stanford University Medical Center, Palo Alto, California

    Locations

    14 in total

    Run by

    New York Medical College

    See if you can join NCT02249923 on ClinicalTrials.gov